B of A Securities Initiates Coverage On Agios Pharmaceuticals with Buy Rating, Announces Price Target of $54
B of A Securities analyst Greg Harrison initiates coverage on Agios Pharmaceuticals (NASDAQ:AGIO) with a Buy rating and announces Price Target of $54.
Earnings Scheduled For November 3, 2021
Companies Reporting Before The Bell
• R.R.Donnelley & Sons (NYSE:RRD) is likely to report quarterly earnings at $0.32 per share on revenue of $1.19 billion.
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected.
The Daily Biotech Pulse: AzurRx Jumps On Data, Agios’ Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 17)
Agios’ Rare Anemia Drug Application Under FDA Priority Review
The FDA has accepted Agios Pharmaceuticals Inc’s (NASDAQ:AGIO) marketing application seeking approval for mitapivat for pyruvate kinase (PK) deficiency. Under Priority…
Goldman Sachs Downgrades Agios Pharmaceuticals to Sell, Lowers Price Target to $39
Goldman Sachs analyst Salveen Richter downgrades Agios Pharmaceuticals (NASDAQ:AGIO) from Neutral to Sell and lowers the price target from $58 to $39.
Earnings Scheduled For July 29, 2021
Companies Reporting Before The Bell
• Smith & Nephew (NYSE:SNN) is projected to report earnings for its second quarter.
The Week Ahead In Biotech (July 25-31): Big Pharma Earnings, Iterum FDA Decision, Alzheimer’s Conference, IPOs and More
Biotech stocks rebounded in the week ended July 23, thanks to the broader market strength. The sector also benefitted from the optimism that was set in motion by the solid start to the pharma reporting season.
Raymond James Initiates Coverage On Agios Pharmaceuticals with Market Perform Rating
Raymond James analyst Danielle Brill initiates coverage on Agios Pharmaceuticals (NASDAQ:AGIO) with a Market Perform rating.